(NASDAQ:BLUE – Get Free Report) had its target price dropped by analysts at Wells Fargo & Company from $40.00 to $5.00 in a ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...

Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Bluebird Bio (BLUE) to $5 from $40 and keeps an Equal Weight rating on the ...

Bluebird Bio, a company that steered three gene therapies to FDA approval but struggled to commercialize them, has found the cash it needs to put those therapies on stronger financial footing by ...

JPMorgan upgraded Bluebird Bio (BLUE) to Neutral from Underweight without a price target after the company entered into a definitive agreement ...

Somerville gene therapy company bluebird bio, once among the highest-profile biotechs in the Boston area, has agreed to be ...

Bluebird Bio announced it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...